Home » J&J’s Janssen Buys Rights to Hepatitis C Compound from GSK
J&J’s Janssen Buys Rights to Hepatitis C Compound from GSK
Johnson & Johnson’s Janssen subsidiary has acquired GlaxoSmithKline’s GSK2336805, a daily replication complex inhibitor aimed at treating hepatitis C.
Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News
Upcoming Events
-
07May
-
14May
-
30May